In addition to reducing the potential for CDK4/6i-driven hematological toxicities, a shorter CDK4/6i schedule would be sufficient to induce transcriptional changes that facilitate immune engagement, while allowing longer periods for CTLs to expand efficiently to carry out their anti-tumor effector function. The gene discussed is CDK4; the disease is neoplasm.